<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cannabis (marijuana): Acute intoxication</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cannabis (marijuana): Acute intoxication</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cannabis (marijuana): Acute intoxication</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George Sam Wang, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evan Schwarz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2257999184"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic discusses the epidemiology, toxicity, clinical manifestations, and management of acute intoxication with cannabis.</p><p>Related topics are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>The clinical manifestations and management of toxicity from synthetic cannabinoids (see  <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">"Synthetic cannabinoids: Acute intoxication"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cannabis use and cannabis use disorder (see  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cannabis withdrawal (see  <a class="medical medical_review" href="/z/d/html/114326.html" rel="external">"Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cannabinoid hyperemesis syndrome (see  <a class="medical medical_review" href="/z/d/html/141176.html" rel="external">"Cannabinoid hyperemesis syndrome"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical use of cannabis and cannabinoids (see  <a class="medical medical_review" href="/z/d/html/126970.html" rel="external">"Medical use of cannabis and cannabinoids in adults"</a>)</p><p></p><p class="headingAnchor" id="H455434631"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>According to the World Health Organization (WHO), 147 million people, or 2.5 percent of the world population, use cannabis, making it the world's most widely cultivated, trafficked, and abused illicit substance [<a href="#rid1">1</a>]. Use is high in the adolescent age group. As an example, among surveyed adolescents in the United States, approximately 5 percent of 8<sup>th</sup> graders, 12 percent of 10<sup>th</sup> graders, and 20 percent of 12<sup>th</sup> graders reported cannabis use in the past month [<a href="#rid2">2</a>].</p><p>Some countries have legalized cannabis, including Uruguay and Canada [<a href="#rid3">3,4</a>]. At the United States federal level, cannabis products are classified as Schedule I (ie, no currently accepted medical use and a high potential for abuse) [<a href="#rid3">3,5,6</a>]. However, over 30 states have decriminalized <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">medical cannabis</a> or are reviewing legislation to allow low-dose delta-9 tetrahydrocannabinol (THC) products for specific medicinal indications, and many states have allowed the retail sale and possession of recreational cannabis. (See  <a class="medical medical_review" href="/z/d/html/126970.html" rel="external">"Medical use of cannabis and cannabinoids in adults", section on 'Medical cannabis policy in the United States'</a>.)</p><p>The public health impact of decriminalization or legalization of recreational cannabis use includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Both decriminalization and legalized recreational use have been associated with increased unintentional pediatric ingestions [<a href="#rid7">7-18</a>]. As an example, after legalization of recreational cannabis use in Colorado, annual calls to the regional poison control center for pediatric cannabis exposure increased 34 percent on average to 6 cases per 100,000 population, which was almost twice the rate for the rest of the United States [<a href="#rid9">9</a>]. Exposure to recreational cannabis accounted for about half of cases. Rates of hospital visits at a large regional children's hospital system also increased significantly during the period of the study, although the total number of presenting patients (81) was small. Hospitalizations, including intensive care unit admissions, have also increased [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of cannabis legalization on prevalence of use among youth is mixed. In regions with <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">medical cannabis</a> availability, diversion of drug from registered users may encourage adolescent abuse [<a href="#rid21">21</a>]. The National Survey on Drug Use and Health cross-sectional survey reported a small increase in cannabis use disorder in the adolescent and young adult population in the regions of the United States that have legalized recreational cannabis [<a href="#rid22">22</a>]. On the other hand, a separately administered high school survey in Colorado reported a decrease in past-month use from 20 percent in 2019 to 13 percent in 2021. However, past 30-day cannabis vaping increased from 35 to 39 percent among cannabis users [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 1 in 20 pregnant women report cannabis use some time during pregnancy, most commonly during the first trimester. The prevalence of use in this population has continued to increase in the United States, increasing from 3 to 7 percent between 2002 and 2017 [<a href="#rid24">24</a>]. Approximately 0.5 percent of pregnant females report past-month cannabis use for medical-only purposes. Common reasons for use included self-treatment of stress, anxiety, nausea, vomiting, and pain. (See  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Cannabis (marijuana)'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In other countries where cannabis can be used legally, rates of usage vary. In the European Union, cannabis use in 2020 for those aged 15 to 34 was estimated at 15.4 percent, ranging from 3.4 percent in Hungary to 21.8 percent in France [<a href="#rid25">25</a>]. As concentrated hashish resin has become more available in France, a corresponding increase in the number of annual admissions and severity of symptoms has occurred among infants and young children [<a href="#rid26">26,27</a>]. In Canada in 2022, for those greater than 16 years of age, more than 19 percent reported use in the past 30 days [<a href="#rid28">28</a>]. Thus, the impact of decriminalization or legalization on the subsequent prevalence of cannabis use is not easily predicted and varies depending upon the specifics of enacted regulations [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H455434637"><span class="h1">PHARMACOLOGY AND TOXICITY</span></p><p class="headingAnchor" id="H455434643"><span class="h2">Site of action</span><span class="headingEndMark"> — </span>The cannabinoid receptor is a G-protein-coupled receptor, which inhibits adenylyl cyclase and stimulates potassium conductance. There are two known cannabinoid receptors: CB1 and CB2 [<a href="#rid29">29-31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CB1 is found in the central nervous system including the basal ganglia, substantia nigra, cerebellum, hippocampus, and cerebral cortex. It acts presynaptically and inhibits release of several neurotransmitters including acetylcholine, L-glutamate, gamma amino butyric acid (GABA), norepinephrine, dopamine, and 5-hydroxytryptamine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CB2 is found peripherally in the immune system tissues (eg, splenic macrophages and B lymphocytes), peripheral nerve terminals, and vas deferens. It is postulated that it plays a role in regulation of immune responses and inflammatory reactions. Anandamide and palmitoylethanolamide are known endogenous cannabinoid receptor ligands.</p><p></p><p class="headingAnchor" id="H455434649"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Delta-9 tetrahydrocannabinol (THC) is the most psychoactive cannabinoid. The pharmacokinetics and pharmacodynamics of THC vary by route of exposure as follows [<a href="#rid29">29,31-39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled cannabis</strong> – After inhalation of cannabis smoke, onset of psychoactive effects occurs rapidly, with peak effects felt at 15 to 30 minutes and lasting up to four hours. These effects mirror plasma THC concentrations. Approximately 2 to 3 mg of inhaled THC is sufficient to produce drug effects in a naïve user. Pulmonary bioavailability varies from 10 to 35 percent of an inhaled dose and is determined by the depth of inhalation along with the duration of puffing and breath holding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ingested cannabis</strong> – When compared with inhalation, cannabis ingestion has a delayed onset of psychoactive effects that ranges from 30 minutes to three hours. Clinical effects may last up to 12 hours. Orally administered cannabis has low bioavailability (5 to 20 percent) because of chemical degradation in gastric acid and substantial first-pass metabolism in the liver. In naïve users, psychotropic effects occur with 5 to 20 mg of ingested THC.</p><p></p><p>THC is lipid soluble, highly protein bound (95 to 99 percent), and has a volume of distribution of 2.5 to 3.5 L/kg [<a href="#rid29">29,35</a>].</p><p>THC metabolism occurs via hepatic cytochrome oxidases, CYP2C9 and 3A4. The primary active metabolite is 11-hydroxy THC (11-OH THC), and the inactivated metabolite is THC-carboxylic acid (THC-COOH) [<a href="#rid29">29</a>]. After metabolism, THC is mostly excreted as hydroxylated and carboxylated metabolites via feces (65 percent) and urine (20 percent) [<a href="#rid29">29</a>]. Although difficult to measure, the acute elimination half-life of THC is slow, ranging from 25 to 36 hours [<a href="#rid29">29</a>]. This lengthy half-life is likely due to slow release from lipid storage compartments and enterohepatic circulation. Elimination half-life is longer in regular cannabis users. Potential pharmacokinetic interactions for THC and cannabidiol (CBD) are provided in the table  (<a class="graphic graphic_table graphicRef141329" href="/z/d/graphic/141329.html" rel="external">table 1</a>).</p><p>THC crosses the placenta with fetal plasma concentrations 10 to 30 percent of maternal concentrations. Limited data demonstrate that THC also accumulates in breast milk, peaking at four hours after maternal smoking, and can be detectable in breast milk at least six days after last maternal use. In one cohort, the estimated mean half-life of THC in breast milk was over two weeks [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/5010.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Cannabis (marijuana)'</a>.) </p><p class="headingAnchor" id="H2361926953"><span class="h2">Cannabis formulations</span><span class="headingEndMark"> — </span>There are a variety of subspecies and strains of cannabis; <em>Cannabis sativa</em> is one of the most commonly used for recreational purposes. Cannabis sativa contains over 500 different clinical compounds and over 60 known cannabinoids; of these, THC is the most psychoactive and is responsible for most symptoms of intoxication [<a href="#rid29">29,33</a>].</p><p>The dried flower of the cannabis plant has a large range of THC content, ranging from 1 to 20 percent of the total weight; however, much variability exists among cannabis samples [<a href="#rid41">41</a>]. In general, cannabis potency has increased over the past 20 years [<a href="#rid42">42</a>]. Common slang terms for cannabis include "pot," "grass," "dope," "MJ," "Mary Jane," "doobie," "hooch," "weed," "hash," "reefer," and "ganja."</p><p>Delta-8 THC is typically a minor cannabinoid found in cannabis. It is less potent compared with delta-9 THC but can have similar psychoactive effects (eg, lethargy, tachycardia, ataxia, and psychosis) in higher doses. It is increasingly found in United States cannabis products, often marketed as low delta-9 THC [<a href="#rid43">43-46</a>]. It can be synthesized, most often from cannabidiol (CBD).</p><p>Delta-10 THC has similar potency and characteristics as delta-8 THC. Compared with delta-8 THC, it is not as prevalent or considered a public health concern.</p><p>Synthetic chemicals that are cannabinoid receptor agonists called "synthetic cannabinoids" may have been available in Europe as early as 2004 and were first reported in the United States in December 2008. More than 200 distinct synthetic cannabinoids have been identified. The clinical effects can be similar to natural cannabis intoxication but may also result in more severe life-threatening symptoms. Acute intoxication from synthetic cannabinoids is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">"Synthetic cannabinoids: Acute intoxication"</a>.)</p><p class="headingAnchor" id="H2371777890"><span class="h3">Recreational use</span><span class="headingEndMark"> — </span>Recreational cannabis use often consists of smoking the dried flower in the form of rolled cigarettes (joints) and water bongs [<a href="#rid47">47</a>]. THC is also extracted using various solvents (butane, ethanol, hexane, isopropanol) to create highly concentrated products (60 to 99 percent of THC by weight) including oils and tinctures called "wax," "dabs," "budder," and "shatters" [<a href="#rid48">48-50</a>]. In addition to being smoked, these highly concentrated products are vaporized (eg, using electronic cigarettes [<a href="#rid51">51,52</a>]) or mixed in food products (such as baked goods, candies, and other food and beverages) and ingested ("edibles").</p><p>In regions where cannabis use is legal, concentrated forms are popular and may pose a risk of unintentional ingestion by young children or excessive use by adolescents and adults [<a href="#rid53">53-55</a>]. As an example, in Colorado, some companies have produced packaging for cannabis products that mimic popular candy, although state law prohibits packaging and advertising that targets children [<a href="#rid56">56</a>]. Furthermore, many of these products contain up to four times the suggested adult serving size dose of 5 to 10 mg. Cannabis edible product ingestions have significantly increased in young children, with a greater proportion of calls due to edible product ingestion in states in the United States and provinces in Canada that have legalized cannabis [<a href="#rid14">14,16,17</a>].</p><p class="headingAnchor" id="H2371777896"><span class="h3">Medicinal use</span><span class="headingEndMark"> — </span>Medicinal cannabis is commonly used for chronic pain, nausea, seizure disorders, and other applications. <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">Medical cannabis</a> has varying concentrations and ratios of cannabinoids. It is supplied in various cannabinoid-based medications approved for use by the US Food and Drug Administration (FDA) and many other non-FDA regulated formulations derived from the <em>Cannabis sativa</em> plant. Medicinal use of cannabis and cannabinoids is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/126970.html" rel="external">"Medical use of cannabis and cannabinoids in adults"</a>.)</p><p class="headingAnchor" id="H178487368"><span class="h2">Toxic effects</span><span class="headingEndMark"> — </span>Recreational cannabis intake to achieve psychoactive effects can often result in adverse effects because there is no clear demarcation between doses that achieve symptoms desired by a cannabis user and noxious effects.</p><p>In adolescents and adults, inhaled doses of 2 to 3 mg of THC and ingested doses of 5 to 20 mg of THC impair attention, concentration, short-term memory, and executive functioning [<a href="#rid29">29,31-39,57-63</a>]. More severe adverse effects may occur at doses &gt;7.5 mg/m<sup>2</sup> of THC, including nausea, postural hypotension, delirium, panic attacks, anxiety, and myoclonic jerking [<a href="#rid58">58,59</a>]. Acute psychosis has also been associated with use of higher potency/concentrated cannabis products [<a href="#rid64">64,65</a>].</p><p>Toxicity in children is most often reported after ingestion of a highly concentrated food product [<a href="#rid7">7,8,14,66-71</a>] or hashish resin [<a href="#rid26">26</a>]. Estimated oral doses from 5 to 300 mg in pediatrics have caused a range of symptoms such as mild sleepiness, ataxia, behavior changes, excessive and purposeless motor activity of the extremities (hyperkinesis), coma, and respiratory depression with more severe intoxication correlated with higher estimated doses. For example, in a retrospective study of 80 children &lt;6 years old with edible cannabis ingestions, a THC dose ≥1.7 mg/kg and a dose ≥2.3 mg/kg had a high sensitivity and specificity for duration of symptoms beyond six hours and severe toxicity (eg, cardiovascular effects, respiratory depression, neurologic effects requiring intervention), respectively [<a href="#rid72">72</a>]. In a small study of children and adolescents presenting to an emergency department for acute cannabis intoxication, those without prior THC exposure more commonly had lethargy or somnolence and had a longer duration of clinical symptoms [<a href="#rid73">73</a>]. </p><p>Non-FDA-approved CBD products are widely used for various medical ailments and indications. The only CBD product FDA-approved for use in the US is for the treatment for refractory epilepsy [<a href="#rid74">74</a>]. Based on clinical trial data, common side effects (&gt;10 percent of patients) included vomiting, fatigue, pyrexia, decreased appetite, convulsion, lethargy, somnolence, and diarrhea [<a href="#rid75">75</a>]. A combination THC/CBD buccal spray is available outside the US as a prescription medication for spasticity treatment. Based on United States poison center data from 2014 to 2021, exposure calls related to non-FDA-approved CBD have increased; reported symptoms included tachycardia, central nervous system depression, confusion, and vomiting [<a href="#rid76">76</a>]. Since non-FDA-approved CBD products are unregulated, other ingredients (including other cannabinoids) may have been in these products, which may contribute to or cause the adverse effects.</p><p class="headingAnchor" id="H455434667"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of acute cannabis intoxication vary according to age.</p><p>Neurologic abnormalities are more prominent in children and include ataxia, excessive and purposeless motor activity of the extremities (hyperkinesis), seizures, lethargy, and prolonged coma, which may be life threatening [<a href="#rid7">7,8,26,66-71</a>].</p><p>Acute cannabis intoxication is an unusual primary complaint in adolescents and adults. Patients who come to medical attention are more likely to have hyperemesis or behavioral problems (eg, dysphoria or agitation) caused by adverse cannabis effects or medical emergencies (eg, bronchospasm or pneumothorax) associated with the method of inhalation. Although rare, chest pain with myocardial infarction in young adults without any prior history of coronary artery abnormalities has been described [<a href="#rid77">77-81</a>]. The issue of causation is unclear, however, in light of the frequency of cannabis use in the general population and the presence of unsuspected atherosclerosis or other cardiac conditions in some of these patients.</p><p class="headingAnchor" id="H7890723"><span class="h2">Children</span><span class="headingEndMark"> — </span>In children, acute cannabis intoxication typically occurs after exploratory ingestion of cannabis intended for adult use [<a href="#rid7">7-9,67-71,82,83</a>]. Less commonly, intentional exposure of children by caretakers, including encouragement of cannabis inhalation to promote sleepiness and to decrease activity, has been reported [<a href="#rid84">84</a>]. Pediatric ingestions of cannabis products happen more frequently in regions with decriminalization or legalization of cannabis use [<a href="#rid7">7-14,85</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p>After limited exposures, children may display sleepiness, euphoria, irritability, and other changes in behavior [<a href="#rid7">7,8,19,20,67-71,82,84-87</a>]. Vital signs may show sympathomimetic effects (eg, tachycardia and hypertension) or, in patients with depressed mental status, bradycardia. Nausea, vomiting, conjunctival injection, nystagmus, ataxia, and (in verbal children) slurred speech may also be present. Dilated pupils have frequently been reported, although miosis has also been described [<a href="#rid86">86,88-90</a>].</p><p>In large overdoses (eg, ingestion of edible products, concentrated oils, or hashish), coma with apnea or depressed respirations can occur [<a href="#rid7">7-9,19,20,26,67-71,83,86,87</a>].</p><p>Although not typical of pediatric cannabis intoxication, seizures have also been reported [<a href="#rid68">68,82,83,89</a>]. In one instance, cocaine was also found on urine screening [<a href="#rid89">89</a>]. In one retrospective series of 29 children under age three admitted with documented cannabis exposure, seizures occurred in four patients, all of whom had ingested hashish resin [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H7890730"><span class="h2">Adolescents and adults</span><span class="headingEndMark"> — </span>The physiologic signs of cannabis intoxication in adolescents and adults can include [<a href="#rid29">29,31,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Increased blood pressure or, especially in older adults, orthostatic hypotension</p><p class="bulletIndent1"><span class="glyph">●</span>Increased respiratory rate</p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival injection (red eye)</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Increased appetite</p><p class="bulletIndent1"><span class="glyph">●</span>Nystagmus</p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia</p><p class="bulletIndent1"><span class="glyph">●</span>Slurred speech</p><p></p><p>Complications associated with cannabis smoking include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute exacerbations and poor symptom control in patients with asthma [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumomediastinum and pneumothorax suggested by tachypnea, chest pain, and subcutaneous emphysemas caused by deep inhalation with breath-holding [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/6352.html" rel="external">"Spontaneous pneumomediastinum in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/117888.html" rel="external">"Pneumothorax: Definitive management and prevention of recurrence"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, angina, myocardial infarction, cardiac dysrhythmias, and ischemic stroke [<a href="#rid93">93-97</a>]. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/6213.html" rel="external">"Ischemic stroke in children and young adults: Epidemiology, etiology, and risk factors"</a>.)</p><p></p><p class="bulletIndent1">The risk for myocardial infarction among regular cannabis users has been found to be significantly elevated over baseline risk in nonusers [<a href="#rid81">81,93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, heavy, acute cannabis use has caused lethargy and hypoventilation [<a href="#rid98">98</a>]. </p><p></p><p>Cannabis intoxication in adolescents and adults also results in the following neuropsychiatric effects:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood, perception, thought content</strong> – Ingestion typically leads to feeling "high," marked by a euphoric, pleasurable feeling and a decrease in anxiety, alertness, depression, and tension. However, first-time cannabis users, as well as anxious or psychologically vulnerable individuals, may experience anxiety, dysphoria, and panic [<a href="#rid32">32</a>]. Increased sociability usually occurs during intoxication, although dysphoric reactions may be accompanied by social withdrawal. Inexperienced users who ingest cannabis products may not be aware that effects may not be felt for up to three hours, which may cause them to continue to consume high-potency products with an increased likelihood of dysphoria. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1">Perceptual changes include the sensation that colors are brighter and music is more vivid [<a href="#rid32">32</a>]. Time perception is distorted in that perceived time is faster than clock time. Spatial perception can also be distorted, and high doses of potent cannabis products may cause hallucinations. Mystical thinking, increased self-consciousness, and depersonalization may occur, as well as transient grandiosity, paranoia, and other signs of psychosis [<a href="#rid32">32,99</a>]. Acute intoxication from THC can also lead to acute psychotic symptoms, which are worsened with higher doses of THC [<a href="#rid65">65,100,101</a>]. (See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects", section on 'Psychiatric effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognition, psychomotor performance</strong> – Cannabis use slows reaction time and impairs attention, concentration, short-term memory, and risk assessment. These effects are additive when cannabis is used in conjunction with other central nervous system depressants [<a href="#rid32">32</a>]. Acute cannabis use also impairs motor coordination and interferes with the ability to complete complex tasks that require divided attention [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1">Impairment of cognition, coordination, and judgment lasts much longer than the subjective mood change of feeling "high." Psychomotor impairment lasts for 12 to 24 hours due to accumulation of cannabis in adipose tissue, slow release of THC from fatty tissue stores, and enterohepatic recirculation. However, a cannabis user may think that they are no longer impaired until several hours after the acute mood-altering effects have resolved. As an example, a placebo-controlled trial with licensed pilots found that smoking cannabis impaired performance on a flight simulator for up to 24 hours, although only one of the nine subjects recognized this impairment [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1">Acute psychomotor impairments interfere with the ability to operate other heavy machinery, such as automobiles, trains, and motorcycles. A meta-analysis of nine studies found an association between cannabis intoxication and an increased risk of a motor vehicle collision involving serious injury or death [<a href="#rid32">32,62,104,105</a>]. Several studies demonstrated that cannabis use negatively impacted simulated driving performance [<a href="#rid106">106-110</a>]. Drivers using cannabis are two to seven times more likely to be responsible for accidents compared with drivers not using any drugs or alcohol [<a href="#rid111">111</a>]. Furthermore, the probability of causing an accident increases with plasma levels of THC [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H455434686"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1101612480"><span class="h2">Children</span><span class="headingEndMark"> — </span>Diagnosis of cannabis intoxication in young children based solely on clinical criteria can be difficult because a history of exposure is often lacking, and the symptoms of cannabis exposure are nonspecific. Thus, ancillary studies are often needed to exclude other causes of altered mental status (see <a class="local">'Other ancillary studies'</a> below). Urine drug screens help confirm the diagnosis because any positive result in a symptomatic child likely represents an acute exposure. (See <a class="local">'Drug testing for cannabinoids'</a> below.)</p><p class="headingAnchor" id="H2152629422"><span class="h2">Adolescents and adults</span><span class="headingEndMark"> — </span>Acute cannabis intoxication is a clinical diagnosis in adolescents and adults. Urine drug screens are less helpful in adolescents and adults for the diagnosis of acute intoxication. Although testing is usually positive several hours after acute exposure, it can also be positive well after symptoms have resolved. As an example, positive results for THC metabolites have been reported up to 10 days after weekly use and up to 25 days after daily use [<a href="#rid112">112</a>]. Thus, cannabis testing does not provide any specific information on the timeline of exposure or correlate with severity of intoxication.</p><p>Pure cannabidiol (CBD) should not result in a positive THC urine drug screen. However, CBD products may contain THC, which will result in a positive urine drug screen [<a href="#rid113">113</a>]. Delta-8 THC may cross-react with standard THC immunoassays [<a href="#rid114">114</a>]. Confirmatory testing evaluating individual cannabinoids and respective metabolites can help determine the specific exposure.</p><p>Selected adolescents and adults with chest pain may warrant an electrocardiogram (ECG), cardiac biomarkers, or chest radiograph to identify associated myocardial ischemia or pneumomediastinum. (See <a class="local">'Other ancillary studies'</a> below.)</p><p class="headingAnchor" id="H3317594865"><span class="h2">Drug testing for cannabinoids</span><span class="headingEndMark"> — </span>Hospital testing for cannabis typically consists of a urine drug screen. (See <a class="local">'Diagnosis'</a> above.) </p><p>Standard urine drug screens that are available in most health care facilities consist of immunoassays that detect THC metabolites, primarily the main metabolite THC-COOH. The lower limits of detection range from 20 to 100 ng/mL, depending upon the specific assay [<a href="#rid115">115</a>]. The Substance Abuse and Mental Health Services Administration (SAMHSA) standard is 50 ng/mL, with confirmatory testing using 15 ng/mL, as the lower limit of detection [<a href="#rid116">116</a>]. Immunoassays for THC do not detect synthetic cannabinoids, which are structurally distinct from THC.</p><p>In situations where a positive screen for cannabis has legal implications or may impact school attendance or sports participation, individuals may claim that the test results from passive inhalation of cannabis smoked by others. In adolescents and adults, it is difficult to achieve sufficient concentrations from secondhand smoke from typical cannabis cigarettes to detect metabolite concentrations above most urine drug screen limits [<a href="#rid117">117-121</a>]. However, studies using products with higher THC content (typical of what is more commonly used since 2005) have not been performed. There has been a case report of an infant becoming symptomatic after passive cannabis smoke exposure [<a href="#rid122">122</a>]. Metabolites of THC have been detectable in a cohort of children hospitalized for bronchiolitis exposed to passive cannabis smoke, although below the limits of detection of standard immunoassays [<a href="#rid123">123</a>].</p><p>False positives for cannabinoids are rare because the chemical structure is unique, and immunoassays are targeted toward metabolites of THC. Historically reported false positives for THC have included <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a>, <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, proton pump inhibitors, hemp seed oil, nonsteroidal anti-inflammatory drugs (NSAIDs), and baby wash products in infants [<a href="#rid124">124-129</a>]. Most package inserts for commercially available immunoassays will list possible false positives for their cannabinoid assay. If required for clinical or social indications, confirmatory testing of urine, blood, or serum can be sent to reference labs by gas chromatography and mass spectrophotometry. However, results of confirmatory testing do not return quickly enough to affect clinical care.</p><p class="headingAnchor" id="H3788439114"><span class="h2">Other ancillary studies</span><span class="headingEndMark"> — </span>Most adolescents and adults do not warrant any testing for the diagnosis or treatment of uncomplicated acute cannabis intoxication. Patients with chest pain suggestive of myocardial ischemia or infarction warrant a 12-lead ECG and possibly cardiac biomarkers (eg, troponin T or I). (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use", section on 'Diagnosis of acute MI'</a>.) </p><p>Chest radiograph may assist in the diagnosis of stable patients with chest pain indicative of a spontaneous pneumothorax. However, patients with signs of a tension pneumothorax should undergo decompression prior to chest radiography. Bedside ultrasound may assist with rapid diagnosis of pneumothorax in these unstable patients. (See  <a class="medical medical_review" href="/z/d/html/14888.html" rel="external">"Bedside pleural ultrasonography: Equipment, technique, and the identification of pleural effusion and pneumothorax"</a>.)</p><p>Children may warrant testing for other potential causes of altered mental status depending upon whether the exposure is known and based upon specific physical findings including rapid blood glucose, electrolytes, blood gas analysis, lumbar puncture, and neuroimaging (eg, computed tomography [CT] of the head). Neuroimaging should be avoided in known cannabis exposures unless focal neurologic findings are also present or concerns for other etiologies such as head trauma exist. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H455434692"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H455434699"><span class="h2">Children</span><span class="headingEndMark"> — </span>The differential diagnosis for cannabis exposure in children is broad because toxicity most commonly presents as altered behavior, lethargy, or coma. When history of exposure is lacking, a positive rapid urine drug screen for cannabinoids is helpful for identifying cannabis as the likely culprit in children too young to be using cannabis recreationally. (See <a class="local">'Drug testing for cannabinoids'</a> above.)</p><p>Some common medical causes of lethargy and coma are listed here with features that distinguish them from cannabis intoxication (see  <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children", section on 'Etiologies'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – Low rapid blood sugar (see  <a class="medical medical_review" href="/z/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte imbalance</strong> (eg, hyponatremia or hypocalcemia) – Low serum sodium or calcium (see  <a class="medical medical_review" href="/z/d/html/14277.html" rel="external">"Hyponatremia in children: Etiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system infection</strong> (eg, meningitis or encephalitis) – Fever and/or meningismus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Traumatic brain injury, especially abusive head trauma</strong> – Child abuse may present with intracranial injury (eg, subdural hematoma) without an appropriate mechanism by history, retinal hemorrhages, skin bruising, and/or fractures (see  <a class="medical medical_review" href="/z/d/html/6610.html" rel="external">"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children", section on 'Clinical features'</a>)</p><p></p><p>A positive urine drug screen for metabolites of cannabis also helps differentiate cannabis intoxication from poisoning with other agents but is not immediately available in most facilities. Toxicologic causes of lethargy and coma in children are extensive  (<a class="graphic graphic_table graphicRef80618" href="/z/d/graphic/80618.html" rel="external">table 2</a>). The following agents and important clinical features that distinguish them from cannabis intoxication include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids</strong> – Lethargy and coma following cannabis ingestion does not respond to <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, which differentiates it from toxicity caused by opioid analgesics. (See  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedative/hypnotic agents</strong> – Cannabis toxicity typically causes more tachycardia or seizure-like activity than sedatives/hypnotics. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/335.html" rel="external">"Meprobamate poisoning", section on 'Clinical features of overdose'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethanol</strong> – A sickly sweet breath odor, hypoglycemia (when present), and an elevated blood alcohol concentration are important findings of ethanol intoxication. (See  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral hypoglycemic agents</strong> – Patients typically have a normal mental status and examination unless hypoglycemia is present. Cannabis intoxication is <strong>not</strong> associated with hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/308.html" rel="external">"Sulfonylurea agent poisoning", section on 'History and physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonidine</strong><strong> </strong>– Some patients with coma from <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> poisoning will respond to <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> administration. Patients will also show more signs of hemodynamic instability such as bradycardia and hypotension. (See  <a class="medical medical_review" href="/z/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihistamines </strong>–<strong> </strong>Significant toxicity is often associated with anticholinergic findings (dilated pupils, flushing, dry skin and mouth, decreased breath sounds, and delirium with seizures). (See  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning", section on 'Clinical features of overdose'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbon monoxide</strong> – Other members of the household may have flu-like symptoms in patients with carbon monoxide poisoning, and carboxyhemoglobin will be elevated. (See  <a class="medical medical_review" href="/z/d/html/322.html" rel="external">"Carbon monoxide poisoning", section on 'Clinical findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychotropic agents (eg, antipsychotic or antidepressant agents)</strong> – These agents often are associated with anticholinergic findings as described above and may be associated with arrhythmias or electrocardiographic (ECG) abnormalities (eg, prolonged QRS or QT intervals). (See  <a class="medical medical_review" href="/z/d/html/315.html" rel="external">"First-generation (typical) antipsychotic medication poisoning", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/304.html" rel="external">"Second-generation (atypical) antipsychotic medication poisoning", section on 'Clinical features of overdose'</a>.)</p><p></p><p class="headingAnchor" id="H455434705"><span class="h2">Adolescents and adults</span><span class="headingEndMark"> — </span>Several other commonly used recreational drugs have some overlapping clinical features with cannabis intoxication in adolescents and adults, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cocaine (see  <a class="medical medical_review" href="/z/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Clinical manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amphetamines and methcathinones (bath salts) (see  <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lysergic acid diethylamide (LSD) and other hallucinogens (eg, phencyclidine [PCP], <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a>, or psilocybin) (see  <a class="medical medical_review" href="/z/d/html/317.html" rel="external">"Intoxication from LSD and other common hallucinogens", section on 'General clinical features of intoxication'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MDMA (ecstasy) (see  <a class="medical medical_review" href="/z/d/html/302.html" rel="external">"MDMA (ecstasy) intoxication", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Synthetic cannabinoids (see  <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">"Synthetic cannabinoids: Acute intoxication", section on 'Clinical manifestations'</a>)</p><p></p><p>Cannabis is frequently used recreationally with these drugs or may serve as a vehicle for use (eg, lacing cannabis cigarettes with PCP). Thus, investigation for other intoxicants may be indicated if symptoms are prolonged beyond a few hours or if other marked physiologic abnormalities exist such as hyperthermia, acidosis, significant rhabdomyolysis, or end-organ toxicity.</p><p>Synthetic cannabinoids (eg, Spice or K2) cause findings that are very similar to cannabis intoxication but are more frequently associated with more pronounced sympathomimetic effects, aggressive behavior and agitation, dystonia, and seizures. A urine drug screen for cannabinoids will be negative after synthetic cannabinoid use. (See  <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">"Synthetic cannabinoids: Acute intoxication", section on 'Clinical manifestations'</a>.) </p><p>Cannabis use may exacerbate pre-existing mental illness (eg, psychosis, anxiety, or depression). Thus, clinicians should ask about cannabis use in patients who display new onset or worsening of known psychiatric disease.</p><p class="headingAnchor" id="H455434711"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of cannabis intoxication consists of supportive care. Because of the differences in toxic manifestations, the management differs significantly by age.</p><p class="headingAnchor" id="H455434744"><span class="h2">Children</span><span class="headingEndMark"> — </span>Children with cannabis exposure are much more likely to demonstrate severe or life-threatening toxicity consisting of excessive and purposeless motor activity (hyperkinesis), seizures, or deep coma. Consultation with a regional poison control center and a medical toxicologist is encouraged for all symptomatic exposures. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H2437149"><span class="h3">Central nervous system depression</span><span class="headingEndMark"> — </span>Severe central nervous system depression from cannabis exposure is unique to the pediatric population and can present with profound depression, lethargy, and coma.</p><p>Treatment is supportive and consists of the following measures:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain airway, breathing, and circulation. Patients with lethargy and coma should receive supplemental oxygen, assessment and support of airway and breathing, and vascular access. Patients with apnea or at risk for aspiration should undergo rapid sequence endotracheal intubation and receive assisted ventilation  (<a class="graphic graphic_table graphicRef51456" href="/z/d/graphic/51456.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measure rapid blood glucose to exclude hypoglycemia  (<a class="graphic graphic_table graphicRef83485" href="/z/d/graphic/83485.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to patients presenting with features of opioid intoxication. Naloxone will <strong>not</strong> reverse coma due to cannabis toxicity  (<a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">table 5</a>).</p><p></p><p>The duration of coma is typically one to two days [<a href="#rid69">69,70,88,89</a>]. Full recovery is expected with supportive care.</p><p class="headingAnchor" id="H455434764"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Seizures have rarely been described after cannabis intoxication in children and may be associated with co-ingestants (eg, cocaine) [<a href="#rid26">26,68,70,89</a>]. Initial treatment of toxin-associated seizures consists of benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>). If seizures persist despite multiple doses of benzodiazepines, then treatment for status epilepticus caused by toxins, as described in the table and algorithm, is warranted  (<a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">table 6</a> and <a class="graphic graphic_algorithm graphicRef131955" href="/z/d/graphic/131955.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p class="headingAnchor" id="H2437132"><span class="h3">Agitation</span><span class="headingEndMark"> — </span>Dysphoria with agitation is not a common presentation in pediatric cannabis exposure. However, if symptoms of marked anxiety or agitation develop, benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) are frequently effective and have a low adverse effect profile.</p><p class="headingAnchor" id="H455434783"><span class="h2">Adolescents and adults</span></p><p class="headingAnchor" id="H2437113"><span class="h3">Mild intoxication</span><span class="headingEndMark"> — </span>Mild intoxication with dysphoria is a common presentation in either naïve or chronic cannabis users after ingestion or inhalation of a high-potency product such as an edible or concentrate. Most patients can be managed with a dimly lit room, reassurance, and decreased stimulation. Short-acting benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) can be helpful in controlling symptoms of anxiety and have a low side effect profile.</p><p class="headingAnchor" id="H2437120"><span class="h3">Severe intoxication</span><span class="headingEndMark"> — </span>Severe physiologic effects are rare after cannabis use, and their presence should prompt the clinician to consider co-ingestion of other recreational drugs (including cocaine, amphetamines, and phencyclidine) or coexisting mental illness. (See <a class="local">'Adolescents and adults'</a> above.)</p><p>Marked agitation or violent behavior not responsive to reassurance and benzodiazepines may necessitate the use of other medications, depending upon the cause, and is rarely encountered with intoxication from cannabis alone. The approach to management of the acutely agitated or violent adult is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a>.)</p><p class="headingAnchor" id="H2438932"><span class="h3">Chest pain</span><span class="headingEndMark"> — </span>Chest pain in association with cannabis use should be managed according to etiology as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute coronary syndrome</strong> – Substernal squeezing chest pain suggestive of myocardial ischemia or infarction may occur rarely in association with cannabis use [<a href="#rid77">77,78,80,81,94,95</a>]. Patients complaining of chest pain suggestive of coronary insufficiency should be evaluated for acute coronary syndrome and treated accordingly  (<a class="graphic graphic_table graphicRef75032" href="/z/d/graphic/75032.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumothorax or pneumomediastinum</strong> – Inhalation and breath-holding during cannabis use may cause a pneumothorax or pneumomediastinum with sharp, pleuritic chest pain and subcutaneous crepitus. Management of a pneumothorax depends upon its size and includes oxygen administration and, if necessary, evacuation with needle decompression or chest tube insertion. (See  <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults", section on 'Initial management of first event'</a>.)</p><p></p><p class="bulletIndent1">No specific treatment is necessary for uncomplicated pneumomediastinum. (See  <a class="medical medical_review" href="/z/d/html/6352.html" rel="external">"Spontaneous pneumomediastinum in children and adolescents", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma exacerbation</strong> – Cannabis use may cause chest tightness with bronchospasm and wheezing. Standard therapy for status asthmaticus should be provided  (<a class="graphic graphic_table graphicRef54125" href="/z/d/graphic/54125.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a>.)</p><p></p><p class="headingAnchor" id="H182085511"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>Activated charcoal has little efficacy in patients with symptomatic cannabis intoxication because they generally present well after the time of ingestion (three hours or longer). In young children, clinical toxicity after ingestion may also include rapid onset of altered mental status or vomiting, which may raise the risk of aspiration if activated charcoal is administered. In addition, the clinical effects of cannabis ingestion are often self-limited without gastrointestinal decontamination, and good outcomes occur with supportive care alone. </p><p>There is no role for gastrointestinal decontamination after toxicity caused by inhaled cannabis.</p><p class="headingAnchor" id="H455434828"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Disposition is determined by several factors including patient age, social circumstances, duration of toxicity, and type of symptoms as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – The duration of symptoms after acute cannabis exposure in children can vary from 4 to 48 hours depending upon the dose ingested [<a href="#rid7">7,8,72,73</a>]. Patients with persistent vomiting, altered mental status, seizures, or excessive, purposeless motor activity (hyperkinesis) warrant hospital admission.</p><p></p><p class="bulletIndent1">Patients who remain asymptomatic or become asymptomatic following exploratory ingestion of legally acquired cannabis products may be discharged after a brief observation period (eg, four to six hours after ingestion).</p><p></p><p class="bulletIndent1">Regardless of whether cannabis is legal in a given jurisdiction, any concerns about the nature of a cannabis exposure in a child warrant involvement of a child abuse or social work team to determine additional social evaluation and potential need for reporting to child protection services. (See  <a class="medical medical_review" href="/z/d/html/6604.html" rel="external">"Child abuse: Social and medicolegal issues", section on 'Reporting suspected abuse'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents and adults</strong> – Most symptoms after acute cannabis use in adults and adolescents resolve within a few hours and will <strong>not</strong> require hospital admission.</p><p></p><p class="bulletIndent1">Hospital admission may rarely be needed for prolonged delirium or agitation requiring repeated doses of benzodiazepines or antipsychotics. These patients should also be screened for substance use disorders and mood disorders, and, if needed, undergo psychiatric consultation and appropriate referrals to substance-use treatment programs. (See  <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1">The disposition for patients with complications of cannabis use depends upon the degree of illness and response to therapy. Patients with proven myocardial infarction or pneumothorax requiring chest tube thoracostomy warrant hospital admission to an appropriate level of care.</p><p></p><p class="headingAnchor" id="H90608153"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3839717601"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p>The Partnership at Drugfree.org maintains a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdrugfree.org%2Fwp-content%2Fuploads%2F2017%2F02%2FDrug-Guide-for-Parents.pdf%3Fsearch-text%3Dmolly&amp;token=X4qBjtOh6QKLhBVWXrTyjlH%2BlNa4N%2FjjJ79sKrqFRKMxRejkTg8Y6ogffvTIIPPgArFNnZyOPeBwv%2FtqVP6rykMl5OI3CEGLnTIblE%2BquNW%2FSI%2B0vo%2FABYGsdNgDHcmc&amp;TOPIC_ID=97099" target="_blank">drug guide</a> for 40 commonly abused drugs including common slang terms.</p><p class="headingAnchor" id="H980429457"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114308.html" rel="external">"Society guideline links: Cannabis use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112688.html" rel="external">"Society guideline links: Poisoning prevention"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/141174.html" rel="external">"Society guideline links: Medical cannabis and cannabinoids"</a>.)</p><p class="headingAnchor" id="H1467154185"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16444.html" rel="external">"Patient education: Cannabis use disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/131890.html" rel="external">"Patient education: Cannabis hyperemesis syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H178487342"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Serious cannabis intoxication is rare in adolescents and adults. Exploratory ingestions of cannabis products have caused life-threatening toxicity in young children. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – Ingestion of cannabis by young children may cause (see <a class="local">'Children'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Life-threatening coma with apnea or depressed respirations</p><p class="bulletIndent3"><span class="glyph">-</span>Seizures </p><p class="bulletIndent3"><span class="glyph">-</span>Effects of intoxication as described below for older patients (limited exposures)</p><p></p><p class="bulletIndent2">Children may warrant testing for other potential causes of altered mental status depending upon whether the exposure is known and based upon specific physical findings. (See <a class="local">'Other ancillary studies'</a> above and <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adolescents and adults</strong> – Cannabis intoxication in adolescents and adults causes (see <a class="local">'Adolescents and adults'</a> above): </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Tachycardia </p><p class="bulletIndent3"><span class="glyph">-</span>Blood pressure changes (hypertension, or in older adults, orthostatic hypotension) </p><p class="bulletIndent3"><span class="glyph">-</span>Conjunctival injection</p><p class="bulletIndent3"><span class="glyph">-</span>Dry mouth</p><p class="bulletIndent3"><span class="glyph">-</span>Increased appetite</p><p class="bulletIndent3"><span class="glyph">-</span>Nystagmus</p><p class="bulletIndent3"><span class="glyph">-</span>Signs of intoxication such as ataxia, slurred speech, euphoria, perceptual changes, and psychomotor impairment </p><p></p><p class="bulletIndent2">Chest pain may arise from pneumothorax, exacerbation of pulmonary disease such as asthma, or (uncommonly) myocardial ischemia. (See <a class="local">'Adolescents and adults'</a> above.)</p><p></p><p class="bulletIndent2">Investigation for other intoxicants may be indicated if symptoms are prolonged, or if other marked physiologic abnormalities exist such as hyperthermia, acidosis, significant rhabdomyolysis, or end-organ toxicity. Otherwise, no specific testing is necessary. (See <a class="local">'Adolescents and adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Regardless of age, acute cannabis intoxication is a clinical diagnosis. Urine drug screens can be helpful in confirming the diagnosis in young children because any positive result identifies acute exposure in the setting of major toxicity. Urine drug screens are less helpful in adolescents and adults and are not routinely needed for diagnosis or management. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Drug testing for cannabinoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Expected toxicity and treatment differs by age: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Children</strong> – Young children may require management of coma and respiratory depression, which frequently requires endotracheal intubation along with exclusion of hypoglycemia and other causes of altered mental status.</p><p></p><p class="bulletIndent3">In a child with marked anxiety or agitation, we suggest administering a benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Agitation'</a> above.)</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> is also warranted for patients who develop seizures; convulsive status epileptics requires further treatment as summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef131955" href="/z/d/graphic/131955.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.) </p><p></p><p class="bulletIndent3">Any concerns about the nature of a cannabis exposure in a child requires involvement of a child abuse or social work team to determine additional social evaluation and potential need for reporting to child protection services. (See <a class="local">'Disposition'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adolescents and adults</strong> – Mild intoxication with dysphoria can be managed with a dimly lit room, reassurance, and decreased stimulation. In a patient with ongoing anxiety despite these measures, we suggest administering a benzodiazepine (eg, oral <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild intoxication'</a> above.)</p><p></p><p class="bulletIndent3">Marked agitation or violent behavior should prompt consideration of a possible co-ingestion (eg, cocaine, amphetamines, phencyclidine [PCP]) or coexisting mental illness. Management of the acutely agitated or violent adult is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult"</a>.)</p><p></p><p class="bulletIndent3">Chest pain in association with cannabis use requires identification and treatment of the underlying etiology (eg, acute coronary syndrome, pneumothorax, or asthma exacerbation). (See <a class="local">'Chest pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – In a patient who ingests cannabis or cannabis-containing products or food, we suggest <strong>not</strong> administering activated charcoal because of the potential for rapid onset of altered mental status with apnea or seizures in young children and lack of efficacy in otherwise symptomatic patients (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Alcohol, Drugs and Addictive Behaviours Unit. Cannabis. https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis (Accessed on March 22, 2023).</li><li class="breakAll">Johnston, L. D., Miech, R. A., Patrick, M. E., O’Malley, P. M., Schulenberg, J. E., &amp;  Bachman, J. G. (2023). Monitoring the Future national survey results on drug use 1975-2022: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, University of Michigan. https://monitoringthefuture.org/wp-content/uploads/2023/01/mtfoverview2022.pdf (Accessed on April 03, 2023).</li><li><a class="nounderline abstract_t">Joffe A, Yancy WS, American Academy of Pediatrics Committee on Substance Abuse, American Academy of Pediatrics Committee on Adolescence. Legalization of marijuana: potential impact on youth. Pediatrics 2004; 113:e632.</a></li><li class="breakAll">Cannabis laws and regulations. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations.html (Accessed on August 20, 2021).</li><li><a class="nounderline abstract_t">Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc 2012; 87:172.</a></li><li><a class="nounderline abstract_t">Committee on Substance Abuse, Committee on Adolescence, Committee on Substance Abuse Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics 2015; 135:584.</a></li><li><a class="nounderline abstract_t">Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr 2013; 167:630.</a></li><li><a class="nounderline abstract_t">Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. Ann Emerg Med 2014; 63:684.</a></li><li><a class="nounderline abstract_t">Wang GS, Le Lait MC, Deakyne SJ, et al. Unintentional Pediatric Exposures to Marijuana in Colorado, 2009-2015. JAMA Pediatr 2016; 170:e160971.</a></li><li><a class="nounderline abstract_t">Wang GS, Hoyte C, Roosevelt G, Heard K. The Continued Impact of Marijuana Legalization on Unintentional Pediatric Exposures in Colorado. Clin Pediatr (Phila) 2019; 58:114.</a></li><li><a class="nounderline abstract_t">Thomas AA, Von Derau K, Bradford MC, et al. Unintentional Pediatric Marijuana Exposures Prior to and After Legalization and Commercial Availability of Recreational Marijuana in Washington State. J Emerg Med 2019; 56:398.</a></li><li><a class="nounderline abstract_t">Whitehill JM, Harrington C, Lang CJ, et al. Incidence of Pediatric Cannabis Exposure Among Children and Teenagers Aged 0 to 19 Years Before and After Medical Marijuana Legalization in Massachusetts. JAMA Netw Open 2019; 2:e199456.</a></li><li><a class="nounderline abstract_t">Onders B, Casavant MJ, Spiller HA, et al. Marijuana Exposure Among Children Younger Than Six Years in the United States. Clin Pediatr (Phila) 2016; 55:428.</a></li><li><a class="nounderline abstract_t">Whitehill JM, Dilley JA, Brooks-Russell A, et al. Edible Cannabis Exposures Among Children: 2017-2019. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Yeung MEM, Weaver CG, Hartmann R, et al. Emergency Department Pediatric Visits in Alberta for Cannabis After Legalization. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Myran DT, Tanuseputro P, Auger N, et al. Edible Cannabis Legalization and Unintentional Poisonings in Children. N Engl J Med 2022; 387:757.</a></li><li><a class="nounderline abstract_t">Tweet MS, Nemanich A, Wahl M. Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Cohen N, Galvis Blanco L, Davis A, et al. Pediatric cannabis intoxication trends in the pre and post-legalization era. Clin Toxicol (Phila) 2022; 60:53.</a></li><li><a class="nounderline abstract_t">Leonard JB, Laudone T, Hines EQ, Klein-Schwartz W. Critical care interventions in children aged 6 months to 12 years admitted to the pediatric intensive care unit after unintentional cannabis exposures. Clin Toxicol (Phila) 2022; 60:960.</a></li><li><a class="nounderline abstract_t">Bennett CE, Venkataramani A, Henretig FM, et al. Recent Trends in Marijuana-Related Hospital Encounters in Young Children. Acad Pediatr 2022; 22:592.</a></li><li><a class="nounderline abstract_t">Salomonsen-Sautel S, Sakai JT, Thurstone C, et al. Medical marijuana use among adolescents in substance abuse treatment. J Am Acad Child Adolesc Psychiatry 2012; 51:694.</a></li><li><a class="nounderline abstract_t">Cerdá M, Mauro C, Hamilton A, et al. Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016. JAMA Psychiatry 2020; 77:165.</a></li><li class="breakAll">Colorado Monitoring Health Concerns Related to Marijuana. Healthy Kids Colorado Survey (HKCS) data. Youth Marijuana Use in Colorado. https://marijuanahealthreport.colorado.gov/health-data/healthy-kids-colorado-survey-hkcs-data (Accessed on March 22, 2023).</li><li><a class="nounderline abstract_t">Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States. JAMA 2019; 322:167.</a></li><li class="breakAll">European Monitoring Centre for Drugs and Drug Addiction (2021), European Drug Report 2021: Trends and Developments, Publications Office of the European Union, Luxembourg. https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf (Accessed on August 19, 2021).</li><li><a class="nounderline abstract_t">Claudet I, Mouvier S, Labadie M, et al. Unintentional Cannabis Intoxication in Toddlers. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Chartier C, Penouil F, Blanc-Brisset I, et al. Pediatric cannabis poisonings in France: more and more frequent and severe. Clin Toxicol (Phila) 2021; 59:326.</a></li><li class="breakAll">Canadian Cannabis Survey 2022. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2022-summary.html (Accessed on March 22, 2023).</li><li><a class="nounderline abstract_t">Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42:327.</a></li><li><a class="nounderline abstract_t">Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33:195.</a></li><li><a class="nounderline abstract_t">Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585.</a></li><li><a class="nounderline abstract_t">Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101.</a></li><li><a class="nounderline abstract_t">Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007; 4:1770.</a></li><li class="breakAll">http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php (Accessed on July 01, 2014).</li><li><a class="nounderline abstract_t">McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005; 10 Suppl A:15A.</a></li><li><a class="nounderline abstract_t">Schwilke EW, Schwope DM, Karschner EL, et al. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009; 55:2180.</a></li><li><a class="nounderline abstract_t">Tanasescu R, Constantinescu CS. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol 2013; 9:1219.</a></li><li><a class="nounderline abstract_t">Toennes SW, Ramaekers JG, Theunissen EL, et al. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol 2008; 32:470.</a></li><li><a class="nounderline abstract_t">Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend 2009; 103:107.</a></li><li><a class="nounderline abstract_t">Wymore EM, Palmer C, Wang GS, et al. Persistence of Δ-9-Tetrahydrocannabinol in Human Breast Milk. JAMA Pediatr 2021; 175:632.</a></li><li><a class="nounderline abstract_t">van der Pol P, Liebregts N, Brunt T, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014; 109:1101.</a></li><li><a class="nounderline abstract_t">ElSohly MA, Mehmedic Z, Foster S, et al. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol Psychiatry 2016; 79:613.</a></li><li><a class="nounderline abstract_t">Leas EC, Nobles AL, Shi Y, Hendrickson E. Public interest in ∆8-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted ∆9-Tetrahydrocannabinol (delta-9-THC) use. Int J Drug Policy 2022; 101:103557.</a></li><li><a class="nounderline abstract_t">Johnson-Arbor K, Smolinske S. The current state of delta-8 THC. Am J Emerg Med 2022; 56:259.</a></li><li><a class="nounderline abstract_t">LoParco CR, Rossheim ME, Walters ST, et al. Delta-8 tetrahydrocannabinol: a scoping review and commentary. Addiction 2023; 118:1011.</a></li><li><a class="nounderline abstract_t">Kaczor EE, Greene K, Babu KM, et al. Commercial Delta-8 THC Products: an Analysis of Content and Labeling. J Med Toxicol 2024; 20:31.</a></li><li class="breakAll">DrugFacts: Marijuana. National Institute on Drug Abuse. January 2014 http://www.drugabuse.gov/publications/drugfacts/marijuana (Accessed on August 21, 2021).</li><li><a class="nounderline abstract_t">Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav 2014; 39:1430.</a></li><li><a class="nounderline abstract_t">Meier MH, Docherty M, Leischow SJ, et al. Cannabis Concentrate Use in Adolescents. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Cinnamon Bidwell L, YorkWilliams SL, Mueller RL, et al. Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. Addict Behav Rep 2018; 8:102.</a></li><li><a class="nounderline abstract_t">Morean ME, Kong G, Camenga DR, et al. High School Students' Use of Electronic Cigarettes to Vaporize Cannabis. Pediatrics 2015; 136:611.</a></li><li><a class="nounderline abstract_t">Hartman RL, Brown TL, Milavetz G, et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clin Chem 2015; 61:850.</a></li><li><a class="nounderline abstract_t">Borodovsky JT, Lee DC, Crosier BS, et al. U.S. cannabis legalization and use of vaping and edible products among youth. Drug Alcohol Depend 2017; 177:299.</a></li><li><a class="nounderline abstract_t">Knapp AA, Lee DC, Borodovsky JT, et al. Emerging Trends in Cannabis Administration Among Adolescent Cannabis Users. J Adolesc Health 2019; 64:487.</a></li><li><a class="nounderline abstract_t">Vo KT, Horng H, Li K, et al. Cannabis Intoxication Case Series: The Dangers of Edibles Containing Tetrahydrocannabinol. Ann Emerg Med 2018; 71:306.</a></li><li><a class="nounderline abstract_t">MacCoun RJ, Mello MM. Half-baked--the retail promotion of marijuana edibles. N Engl J Med 2015; 372:989.</a></li><li><a class="nounderline abstract_t">Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307:819.</a></li><li><a class="nounderline abstract_t">Devine ML, Dow GJ, Greenberg BR, et al. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clin Pharm 1987; 6:319.</a></li><li><a class="nounderline abstract_t">Dow GJ, Meyers FH, Stanton W, Devine ML. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clin Pharm 1984; 3:14.</a></li><li><a class="nounderline abstract_t">Zuurman L, Ippel AE, Moin E, van Gerven JM. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009; 67:5.</a></li><li><a class="nounderline abstract_t">Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352:1611.</a></li><li><a class="nounderline abstract_t">Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:849.</a></li><li><a class="nounderline abstract_t">Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007; 20:116.</a></li><li><a class="nounderline abstract_t">Barkus E. High-potency cannabis increases the risk of psychosis. Evid Based Ment Health 2016; 19:54.</a></li><li><a class="nounderline abstract_t">Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015; 2:233.</a></li><li><a class="nounderline abstract_t">André C, Jaber-Filho JA, Bento RM, et al. Delirium following ingestion of marijuana present in chocolate cookies. CNS Spectr 2006; 11:262.</a></li><li><a class="nounderline abstract_t">Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur J Emerg Med 2006; 13:177.</a></li><li><a class="nounderline abstract_t">Bonkowsky JL, Sarco D, Pomeroy SL. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care 2005; 21:527.</a></li><li><a class="nounderline abstract_t">Carstairs SD, Fujinaka MK, Keeney GE, Ly BT. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J Emerg Med 2011; 41:e69.</a></li><li><a class="nounderline abstract_t">Macnab A, Anderson E, Susak L. Ingestion of cannabis: a cause of coma in children. Pediatr Emerg Care 1989; 5:238.</a></li><li><a class="nounderline abstract_t">Weinberg D, Lande A, Hilton N, Kerns DL. Intoxication from accidental marijuana ingestion. Pediatrics 1983; 71:848.</a></li><li><a class="nounderline abstract_t">Pepin LC, Simon MW, Banerji S, et al. Toxic Tetrahydrocannabinol (THC) Dose in Pediatric Cannabis Edible Ingestions. Pediatrics 2023; 152.</a></li><li><a class="nounderline abstract_t">Heizer JW, Borgelt LM, Bashqoy F, et al. Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes. Pediatr Emerg Care 2016.</a></li><li class="breakAll">EPIDIOLEX (cannabidiol) oral solution, CX. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf (Accessed on November 17, 2022).</li><li><a class="nounderline abstract_t">Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017; 376:2011.</a></li><li><a class="nounderline abstract_t">Perez-Vilar S, Karami S, Long K, Leishear K. Cannabidiol exposures in the United States, National Poison Data System, July 2014-June 2021. Clin Toxicol (Phila) 2023; 61:123.</a></li><li><a class="nounderline abstract_t">Caldicott DG, Holmes J, Roberts-Thomson KC, Mahar L. Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 2005; 12:236.</a></li><li><a class="nounderline abstract_t">Deharo P, Massoure PL, Fourcade L. Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption. Acta Cardiol 2013; 68:425.</a></li><li><a class="nounderline abstract_t">Bachs L, Mørland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124:200.</a></li><li><a class="nounderline abstract_t">Toce MS, Farias M, Powell AJ, et al. Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy. Pediatr Dev Pathol 2019; 22:80.</a></li><li><a class="nounderline abstract_t">Ladha KS, Mistry N, Wijeysundera DN, et al. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. CMAJ 2021; 193:E1377.</a></li><li><a class="nounderline abstract_t">Claudet I, Le Breton M, Bréhin C, Franchitto N. A 10-year review of cannabis exposure in children under 3-years of age: do we need a more global approach? Eur J Pediatr 2017; 176:553.</a></li><li><a class="nounderline abstract_t">Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol (Phila) 2019; 57:735.</a></li><li><a class="nounderline abstract_t">Blackstone M, Callahan J. An unsteady walk in the park. Pediatr Emerg Care 2008; 24:193.</a></li><li><a class="nounderline abstract_t">Cao D, Srisuma S, Bronstein AC, Hoyte CO. Characterization of edible marijuana product exposures reported to United States poison centers. Clin Toxicol (Phila) 2016; 54:840.</a></li><li><a class="nounderline abstract_t">Richards JR, Smith NE, Moulin AK. Unintentional Cannabis Ingestion in Children: A Systematic Review. J Pediatr 2017; 190:142.</a></li><li><a class="nounderline abstract_t">Leubitz A, Spiller HA, Jolliff H, Casavant M. Prevalence and Clinical Characteristics of Unintentional Ingestion of Marijuana in Children Younger Than 6 Years in States With and Without Legalized Marijuana Laws. Pediatr Emerg Care 2021; 37:e969.</a></li><li><a class="nounderline abstract_t">Le Garrec S, Dauger S, Sachs P. Cannabis poisoning in children. Intensive Care Med 2014; 40:1394.</a></li><li><a class="nounderline abstract_t">Croche Santander B, Alonso Salas MT, Loscertales Abril M. [Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain]. Arch Argent Pediatr 2011; 109:4.</a></li><li><a class="nounderline abstract_t">Renier S, Messi G, Orel P. [Acute cannabis poisoning in a female child]. Minerva Pediatr 1994; 46:335.</a></li><li><a class="nounderline abstract_t">Caponnetto P, Auditore R, Russo C, et al. "Dangerous relationships": asthma and substance abuse. J Addict Dis 2013; 32:158.</a></li><li><a class="nounderline abstract_t">Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc 2013; 10:239.</a></li><li><a class="nounderline abstract_t">Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805.</a></li><li><a class="nounderline abstract_t">Jouanjus E, Lapeyre-Mestre M, Micallef J, French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications*. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014; 3:e000638.</a></li><li><a class="nounderline abstract_t">Frost L, Mostofsky E, Rosenbloom JI, et al. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J 2013; 165:170.</a></li><li><a class="nounderline abstract_t">Richards JR, Blohm E, Toles KA, et al. The association of cannabis use and cardiac dysrhythmias: a systematic review. Clin Toxicol (Phila) 2020; 58:861.</a></li><li><a class="nounderline abstract_t">Singh NN, Pan Y, Muengtaweeponsa S, et al. Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis 2012; 21:555.</a></li><li><a class="nounderline abstract_t">Richards JR, Schandera V, Elder JW. Treatment of acute cannabinoid overdose with naloxone infusion. Toxicology communications 2017; 1:29.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195:488.</a></li><li><a class="nounderline abstract_t">Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry 2020; 7:344.</a></li><li><a class="nounderline abstract_t">Boggs DL, Cortes-Briones JA, Surti T, et al. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans. J Psychopharmacol 2018; 32:1308.</a></li><li><a class="nounderline abstract_t">Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. Aviat Space Environ Med 1991; 62:221.</a></li><li><a class="nounderline abstract_t">Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344:e536.</a></li><li><a class="nounderline abstract_t">Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 2016; 111:1348.</a></li><li><a class="nounderline abstract_t">López-Pelayo H, Campeny E, Oliveras C, et al. Early, Chronic, and Acute Cannabis Exposure and Their Relationship With Cognitive and Behavioral Harms. Front Psychiatry 2021; 12:643556.</a></li><li><a class="nounderline abstract_t">Marcotte TD, Umlauf A, Grelotti DJ, et al. Driving Performance and Cannabis Users' Perception of Safety: A Randomized Clinical Trial. JAMA Psychiatry 2022; 79:201.</a></li><li><a class="nounderline abstract_t">Lenné MG, Dietze PM, Triggs TJ, et al. The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accid Anal Prev 2010; 42:859.</a></li><li><a class="nounderline abstract_t">Ronen A, Gershon P, Drobiner H, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev 2008; 40:926.</a></li><li><a class="nounderline abstract_t">Hartley S, Simon N, Larabi A, et al. Effect of Smoked Cannabis on Vigilance and Accident Risk Using Simulated Driving in Occasional and Chronic Users and the Pharmacokinetic-Pharmacodynamic Relationship. Clin Chem 2019; 65:684.</a></li><li><a class="nounderline abstract_t">Leggett T, United Nations Office on Drugs and Crime. A review of the world cannabis situation. Bull Narc 2006; 58:1.</a></li><li><a class="nounderline abstract_t">Smith-Kielland A, Skuterud B, Mørland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999; 23:323.</a></li><li><a class="nounderline abstract_t">Spindle TR, Cone EJ, Kuntz D, et al. Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis. J Anal Toxicol 2020; 44:109.</a></li><li><a class="nounderline abstract_t">Gussow L. Toxicology Rounds: Your ED Patients Are Likely Using Delta-8-THC. Emergency Medicine News 2021; 43:18.</a></li><li><a class="nounderline abstract_t">Grauwiler SB, Drewe J, Scholer A. Sensitivity and specificity of urinary cannabinoid detection with two immunoassays after controlled oral administration of cannabinoids to humans. Ther Drug Monit 2008; 30:530.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration (SAMHSA). Drug-free workplace guidelines and resources. https://www.samhsa.gov/workplace/resources (Accessed on August 20, 2021).</li><li><a class="nounderline abstract_t">Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 1987; 11:89.</a></li><li><a class="nounderline abstract_t">Mørland J, Bugge A, Skuterud B, et al. Cannabinoids in blood and urine after passive inhalation of Cannabis smoke. J Forensic Sci 1985; 30:997.</a></li><li><a class="nounderline abstract_t">Law B, Mason PA, Moffat AC, et al. Passive inhalation of cannabis smoke. J Pharm Pharmacol 1984; 36:578.</a></li><li><a class="nounderline abstract_t">Mulé SJ, Lomax P, Gross SJ. Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine. J Anal Toxicol 1988; 12:113.</a></li><li><a class="nounderline abstract_t">Röhrich J, Schimmel I, Zörntlein S, et al. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol 2010; 34:196.</a></li><li><a class="nounderline abstract_t">Zarfin Y, Yefet E, Abozaid S, et al. Infant with altered consciousness after cannabis passive inhalation. Child Abuse Negl 2012; 36:81.</a></li><li><a class="nounderline abstract_t">Wilson KM, Torok MR, Wei B, et al. Detecting biomarkers of secondhand marijuana smoke in young children. Pediatr Res 2017; 81:589.</a></li><li><a class="nounderline abstract_t">Schwartz RH, Hawks RL. Laboratory detection of marijuana use. JAMA 1985; 254:788.</a></li><li><a class="nounderline abstract_t">ElSohly MA, deWit H, Wachtel SR, et al. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001; 25:565.</a></li><li><a class="nounderline abstract_t">Oosthuizen NM, Laurens JB. Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol. Ann Clin Biochem 2012; 49:194.</a></li><li><a class="nounderline abstract_t">ElSohly MA. Practical challenges to positive drug tests for marijuana. Clin Chem 2003; 49:1037.</a></li><li><a class="nounderline abstract_t">Cotten SW, Duncan DL, Burch EA, et al. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clin Biochem 2012; 45:605.</a></li><li><a class="nounderline abstract_t">Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387.</a></li></ol></div><div id="topicVersionRevision">Topic 97099 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Alcohol, Drugs and Addictive Behaviours Unit. Cannabis. https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis (Accessed on March 22, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://monitoringthefuture.org/wp-content/uploads/2023/01/mtfoverview2022.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Johnston, L. D., Miech, R. A., Patrick, M. E., O’Malley, P. M., Schulenberg, J. E., &amp;  Bachman, J. G. (2023). Monitoring the Future national survey results on drug use 1975-2022: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, University of Michigan. https://monitoringthefuture.org/wp-content/uploads/2023/01/mtfoverview2022.pdf (Accessed on April 03, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173547" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Legalization of marijuana: potential impact on youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173547" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Legalization of marijuana: potential impact on youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blurred boundaries: the therapeutics and politics of medical marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25624383" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The impact of marijuana policies on youth: clinical, research, and legal update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23712626" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pediatric marijuana exposures in a medical marijuana state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24507243" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of unintentional pediatric exposures with decriminalization of marijuana in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27454910" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unintentional Pediatric Exposures to Marijuana in Colorado, 2009-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30288992" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Continued Impact of Marijuana Legalization on Unintentional Pediatric Exposures in Colorado.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846215" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Unintentional Pediatric Marijuana Exposures Prior to and After Legalization and Commercial Availability of Recreational Marijuana in Washington State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31418807" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of Pediatric Cannabis Exposure Among Children and Teenagers Aged 0 to 19 Years Before and After Medical Marijuana Legalization in Massachusetts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26054783" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Marijuana Exposure Among Children Younger Than Six Years in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33753541" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Edible Cannabis Exposures Among Children: 2017-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34544846" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Emergency Department Pediatric Visits in Alberta for Cannabis After Legalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001718" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Edible Cannabis Legalization and Unintentional Poisonings in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36594224" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34137352" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pediatric cannabis intoxication trends in the pre and post-legalization era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384771" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Critical care interventions in children aged 6 months to 12 years admitted to the pediatric intensive care unit after unintentional cannabis exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34325061" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recent Trends in Marijuana-Related Hospital Encounters in Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22721592" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Medical marijuana use among adolescents in substance abuse treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722000" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722000" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211824" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31211824" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28808073" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Unintentional Cannabis Intoxication in Toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840407" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pediatric cannabis poisonings in France: more and more frequent and severe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840407" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pediatric cannabis poisonings in France: more and more frequent and severe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12648025" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacokinetics and pharmacodynamics of cannabinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23386598" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The pharmacologic and clinical effects of medical cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8972919" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cannabis: pharmacology and toxicology in animals and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157422" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pharmacology and effects of cannabis: a brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712819" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human cannabinoid pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712819" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Human cannabinoid pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16237477" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacokinetics of cannabinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833841" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23621668" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713514" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443132" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33683306" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Persistence ofΔ-9-Tetrahydrocannabinol in Human Breast Milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628797" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903403" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34952279" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Public interest in∆8-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted∆9-Tetrahydrocannabinol (delta-9-THC) use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34247877" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The current state of delta-8 THC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36710464" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Delta-8 tetrahydrocannabinol: a scoping review and commentary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37917314" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Commercial Delta-8 THC Products: an Analysis of Content and Labeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37917314" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Commercial Delta-8 THC Products: an Analysis of Content and Labeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930049" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A new method of cannabis ingestion: the dangers of dabs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31451609" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cannabis Concentrate Use in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30167450" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26347431" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High School Students' Use of Electronic Cigarettes to Vaporize Cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26019183" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28662974" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : U.S. cannabis legalization and use of vaping and edible products among youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30205931" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Emerging Trends in Cannabis Administration Among Adolescent Cannabis Users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29103798" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cannabis Intoxication Case Series: The Dangers of Edibles Containing Tetrahydrocannabinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760351" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Half-baked--the retail promotion of marijuana edibles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6287261" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Presence of delta9-tetrahydrocannabinol in human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2822339" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6321091" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133057" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Biomarkers for the effects of cannabis and THC in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843121" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adverse effects of cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15363608" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adverse effects of cannabis on health: an update of the literature since 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278907" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cannabis and psychosis: an update on course and biological plausible mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036127" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High-potency cannabis increases the risk of psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359901" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641831" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Delirium following ingestion of marijuana present in chocolate cookies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16679885" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Coma due to cannabis toxicity in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16096599" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634020" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602198" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ingestion of cannabis: a cause of coma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6300748" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intoxication from accidental marijuana ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635689" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Toxic Tetrahydrocannabinol (THC) Dose in Pediatric Cannabis Edible Ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050740" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050740" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538134" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537670" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cannabidiol exposures in the United States, National Poison Data System, July 2014-June 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175062" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Keep off the grass: marijuana use and acute cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24187771" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792512" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Acute cardiovascular fatalities following cannabis use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29958511" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34493564" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recent cannabis use and myocardial infarction in young adults: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28210835" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A 10-year review of cannabis exposure in children under 3-years of age: do we need a more global approach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30676820" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acute cannabis toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347502" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : An unsteady walk in the park.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418198" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Characterization of edible marijuana product exposures reported to United States poison centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888560" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Unintentional Cannabis Ingestion in Children: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34908380" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence and Clinical Characteristics of Unintentional Ingestion of Marijuana in Children Younger Than 6 Years in States With and Without Legalized Marijuana Laws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25030096" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cannabis poisoning in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21283933" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : [Accidental cannabis poisoning in children: report of four cases in a tertiary care center from southern Spain].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935250" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : [Acute cannabis poisoning in a female child].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23815423" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : "Dangerous relationships": asthma and substance abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23802821" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of marijuana smoking on the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401936" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Triggering myocardial infarction by marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24760961" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cannabis use: signal of increasing risk of serious cardiovascular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23351819" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Marijuana use and long-term mortality among survivors of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267189" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The association of cannabis use and cardiac dysrhythmias: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367621" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cannabis-related stroke: case series and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of acute cannabinoid overdose with naloxone infusion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of acute cannabinoid overdose with naloxone infusion</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949195" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : High-potency cannabis and the risk of psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32197092" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255720" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849400" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Marijuana carry-over effects on aircraft pilot performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323502" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26878835" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The effects of cannabis intoxication on motor vehicle collision revisited and revised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34434125" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Early, Chronic, and Acute Cannabis Exposure and Their Relationship With Cognitive and Behavioral Harms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35080588" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Driving Performance and Cannabis Users' Perception of Safety: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380913" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18460360" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30872375" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effect of Smoked Cannabis on Vigilance and Accident Risk Using Simulated Driving in Occasional and Chronic Users and the Pharmacokinetic-Pharmacodynamic Relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066071" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A review of the world cannabis situation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10488918" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682266" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Toxicology Rounds: Your ED Patients Are Likely Using Delta-8-THC</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18641545" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Sensitivity and specificity of urinary cannabinoid detection with two immunoassays after controlled oral administration of cannabinoids to humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18641545" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Sensitivity and specificity of urinary cannabinoid detection with two immunoassays after controlled oral administration of cannabinoids to humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037193" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2999292" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cannabinoids in blood and urine after passive inhalation of Cannabis smoke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6149279" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Passive inhalation of cannabis smoke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3386204" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465865" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22391418" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Infant with altered consciousness after cannabis passive inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27911435" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Detecting biomarkers of secondhand marijuana smoke in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2989570" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Laboratory detection of marijuana use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11599601" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067092" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816896" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Practical challenges to positive drug tests for marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465236" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24986836" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : False-positive interferences of common urine drug screen immunoassays: a review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
